Chile’s Power to Break Gilead’s Hep C Patent May Cut Drug Prices

September 12, 2018

A groundbreaking ruling that Chile can authorize other drugmakers to manufacture the hepatitis C drug Sovaldi without Gilead’s consent will increase the pressure on drug manufacturers to lower prices, health campaigners told Bloomberg Law.

Related Stories